Physician profile
Ronald Sue
NPI 1932193893
$916.98
in general payments reported to CMS, 2019-2025
17 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $85.71 · 2021: $69.38 · 2022: $19.77 · 2023: $81.17 · 2024: $70.78 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.49 | 2019-2020 | |
| Amgen INC. | $101.17 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $99.61 | 2019-2025 | |
| Abbvie INC. | $89.75 | 2020-2025 | |
| Lilly USA, LLC | $80.40 | 2023-2024 | Zepbound |
| Cleerly, INC. | $65.44 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2019-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $52.45 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.57 | 2020-2024 | Xifaxan |
| Novo Nordisk INC | $42.08 | 2019-2025 | Wegovy |
| Heartflow, INC. | $41.81 | 2025 | |
| Genentech USA, INC. | $35.55 | 2019-2020 | |
| Abbott Laboratories | $24.41 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $21.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.62 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.13 | 2019 | |
| Eisai INC. | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Sue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.